{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"STEREO-RE-PRO","nct_id":"NCT03438552","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stereo-re-pro-nct03438552. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STEREO-RE-PRO","arms":[{"description":"Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.","label":"SBRT at a total dose of 30 Gy","type":"EXPERIMENTAL"},{"description":"Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.","label":"SBRT at a total dose of 25 Gy","type":"EXPERIMENTAL"},{"description":"Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.","label":"SBRT at a total dose of 36 Gy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-11","type":"ESTIMATED"},"conditions":["Local Recurrence of Malignant Tumor of Prostate"],"enrollment":{"count":57,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Stereotactic Body Radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2024-12-20","lead_sponsor":"UNICANCER","official_title":"Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2027-10-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT.","timeFrame":"18 weeks"},{"measure":"Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate","timeFrame":"6 years"}],"references":[{"citation":"Pasquier D, Le Deley MC, Tresch E, Cormier L, Duterque M, Nenan S, Lartigau E. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol. BMJ Open. 2019 Aug 2;9(8):e026666. doi: 10.1136/bmjopen-2018-026666.","pmid":"31377694","type":"DERIVED"}],"start_date":{"date":"2018-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence","url":"https://clinicaltrials.gov/study/NCT03438552"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stereo-re-pro-nct03438552"}